Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in systemic therapy for psoriasis.

U Mrowietz1

  • 1Department of Dermatology, University of Kiel, Schittenhelmstrasse 7, 24105 Kiel, Germany. umrowietz@dermatology.uni-kiel.de

Clinical and Experimental Dermatology
|June 26, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[On the occasion of Professor Enno Christophers's 90th birthday].

Dermatologie (Heidelberg, Germany)·2026
Same author

Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Measuring well-being in psoriasis: psychometric properties of the WHO-5 questionnaire.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

EczemaPartner - adapting a questionnaire to assess the impact of atopic dermatitis on partners of patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same journal

Real-World Outcomes of Stapokibart-Based Combination Therapy for Bullous Pemphigoid: A Single-Center Retrospective Cohort.

Clinical and experimental dermatology·2026
Same journal

A second case of recessive mosaicism in ABCA12 causing a congenital unilateral epidermal nevus.

Clinical and experimental dermatology·2026
Same journal

Dermatopathology.

Clinical and experimental dermatology·2026
Same journal

Persistent Bilateral Palmar Hyperkeratotic Papules in an Adolescent Male.

Clinical and experimental dermatology·2026
Same journal

Shuddering Attacks in an Infant Treated with Atenolol for Infantile Hemangioma: A Previously Unreported Adverse Effect.

Clinical and experimental dermatology·2026
Same journal

Male genital fixed drug eruption: a systematic review.

Clinical and experimental dermatology·2026
See all related articles

New systemic therapies for psoriasis and psoriatic arthritis are needed. This review evaluates emerging treatments focusing on improved safety, efficacy, and usability for patients with moderate to severe disease.

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Severe psoriasis and psoriatic arthritis necessitate systemic treatments.
  • Existing therapies require improved risk-benefit profiles and long-term safety data.
  • Patients with moderate psoriasis seek easier systemic treatment options.

Purpose of the Study:

  • To provide an overview of novel drugs and compounds for psoriasis treatment.
  • To evaluate the current status and future potential of these new agents.
  • To assess efficacy, tolerability, safety, and usability of emerging psoriasis therapies.

Main Methods:

  • Literature review of new drugs and compound groups for psoriasis.
  • Evaluation of clinical data regarding efficacy and safety.
  • Assessment of usability and tolerability in patient populations.

Related Experiment Videos

Main Results:

  • Several new drug classes show promise for psoriasis management.
  • Emerging therapies aim to offer better risk-benefit ratios.
  • Focus on long-term safety and improved patient experience is evident.

Conclusions:

  • New systemic treatments are crucial for moderate to severe psoriasis.
  • Future therapies must prioritize efficacy, safety, and usability.
  • Ongoing research is vital for advancing psoriasis and psoriatic arthritis care.